[
  {
    "criterion": "Provides a concise and accurate summary of the current data on brentuximab vedotin-based second-line regimens for Hodgkin’s lymphoma.",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Fails to mention the importance of monitoring peripheral neuropathy and neutropenia when using brentuximab vedotin.",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Seeks clarification from the user about the specific information they need, demonstrating an understanding of the user's request.",
    "axis": "context_awareness",
    "point": 6
  },
  {
    "criterion": "Uses technical jargon and complex medical terminology, making it difficult for a non-expert to understand the information.",
    "axis": "communication_quality",
    "point": -5
  },
  {
    "criterion": "Provides a reference to support the information provided, such as a study or trial.",
    "axis": "completeness",
    "point": 4
  },
  {
    "criterion": "Fails to address the user's request for information on using brentuximab vedotin alongside PD-1 blockade for advanced Hodgkin’s.",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Clearly explains the potential side effects of brentuximab vedotin, including peripheral neuropathy and neutropenia.",
    "axis": "communication_quality",
    "point": 7
  },
  {
    "criterion": "Provides information that is not supported by current data or evidence.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Acknowledges the limitations of the available data and the need for further research on brentuximab vedotin-based second-line regimens.",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "Does not provide any information on the potential benefits of brentuximab vedotin-based second-line regimens for Hodgkin’s lymphoma.",
    "axis": "completeness",
    "point": -9
  }
]